Browse > Article
http://dx.doi.org/10.4014/jmb.1708.08044

Madurahydroxylactone, an Inhibitor of Staphylococcus aureus FtsZ from Nonomuraea sp. AN100570  

Kim, Bo-Min (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology)
Choi, Ha-Young (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology)
Kim, Geon-Woo (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology)
Zheng, Chang-Ji (Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Yanbian University College of Pharmacy)
Kim, Young-Ho (Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Yanbian University College of Pharmacy)
Kim, Won-Gon (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology)
Publication Information
Journal of Microbiology and Biotechnology / v.27, no.11, 2017 , pp. 1994-1998 More about this Journal
Abstract
FtsZ, a bacterial cell-division protein, is an attractive antibacterial target. In the screening for an inhibitor of Staphylococcus aureus FtsZ, madurahydroxylactone (1) and its related derivatives 2-5 were isolated from Nonomuraea sp. AN100570. Compound 1 inhibited S. aureus FtsZ with an $IC_{50}$ of $53.4{\mu}M$ and showed potent antibacterial activity against S. aureus and MRSA with an MIC of $1{\mu}g/ml$, whereas 2-5 were weak or inactive. Importantly, 1 induced cell elongation in the cell division phenotype assay, whereas 2-5 did not. It indicates that 1 exhibits its potent antibacterial activity via inhibition of FtsZ, and the hydroxyl group and hydroxylactone ring of 1 are critical for the activity. Thus, madurahydroxylactone is a new type of inhibitor of FtsZ.
Keywords
Madurahydroxylactone; FtsZ; inhibitor; Nonomuraea; antibacterial;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lock RL, Harry EJ. 2008. Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7: 324-338.   DOI
2 Vollmer W. 2006. The prokaryotic cytoskeleton: a putative target for inhibitors and antibiotics? Appl. Microbiol. Biotechnol. 73: 37-47.   DOI
3 Kapoor S, Panda D. 2009. Targeting FtsZ for antibacterial therapy: a promising avenue. Expert Opin. Ther. Targets 13: 1037-1051.   DOI
4 Marchand C, Beutler JA, Wamiru A, Budihas S, Mollmann U, Heinisch L et al. 2008. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother. 52:361-364.   DOI
5 Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis 13: 1840-1846.   DOI
6 Levy SB, Marshall B. 2004. Antibacterial resistance worldwide:causes, challenges and responses. Nat. Med. 10: S122-S129.   DOI
7 Brown ED, Wright GD. 2016. Antibacterial drug discovery in the resistance era. Nature 529: 336-343.   DOI
8 Butler MS, Cooper MA. 2012. Screening strategies to identify new antibiotics. Curr. Drug Targets 13: 373-387.   DOI
9 Sun N, Chan FY, Lu YJ, Neves MA, Lui HK, Wang Y et al. 2014. Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity. PLoS One 9: e97514.   DOI
10 Wang J, Galgoci A, Kodali S, Herath KB, Jayasuriya H, Dorso K, et al. 2003. Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem 278: 44424-44428.   DOI
11 Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, et al. 2005. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280: 39709-39715.   DOI
12 Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D. 2008. Berberine targets assembly of Escherichia coli c ell division protein FtsZ. Biochemistry 47: 3225-3234.   DOI
13 Beuria TK, Santra MK, Panda D. 2005. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 44: 16584-16593.   DOI
14 Heinisch L, Roemer E, Jutten P, Haas W, Werner W, Mollmann U. 1999. Semisynthetic derivatives of madura hydroxylactone and their antibacterial activities. J. Antibiot. (Tokyo) 52: 1029-1041.   DOI
15 Strauss DG, Baum M, Fleck WF. 1986. Butylmaduramycin, a new antibiotic from Actinomadura rubra. J. Basic Microbiol. 26: 169-172.   DOI
16 Zheng CJ, Sohn MJ, Kim WG. 2009. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J. Antimicrob. Chemother. 63: 949-953.   DOI
17 Park YS, Grove CI, Gonzalez-Lopez M, Urgaonkar S, Fettinger JC, Shaw JT. 2011. Synthesis of (-)-viriditoxin: a 6,6'-binaphthopyran-2-one that targets the bacterial cell division protein FtsZ. Angew. Chem. Int. Ed. Engl. 50: 3730-3733.   DOI
18 Stokes NR, Baker N, Bennett JM, Berry J, Collins I, Czaplewski LG, et al. 2013. An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. Antimicrob. Agents Chemother. 57: 317-325.   DOI
19 Fleck WF, Strauss DG, Meyer J, Porstendorfer G. 1978. Fermentation, isolation, and biological activity of maduramycin:a new antibiotic from Actinomadura rubra. Z. Allg. Mikrobiol. 18: 389-398.   DOI
20 Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, et al. 2008. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321: 1673-1675.   DOI